Cancer Medicine and Hematology

cancer medicine and hematology

Harvard Medical School Department of Continuing Education

Earn up to 51.75 AMA PRA Crategory 1 Credits™

Sunday, September 29 - Friday, October 4, 2013at the

Fairmont Copley Plaza Hotel, Boston, MA

under the direction of Robert J. Mayer, M.D.

COURSE OVERVIEWThe continuing deluge of new clinical data on novel cancer therapies, molecular diagnostics tests, and emerging treatment approaches makes it difficult for practicing oncologists to stay current and up-to-date on the rationale behind these advances.

This intensive six-day activity is designed to provide a comprehensive review for practitioners of the clinical, molecular, and pathophysiologic basis for the diagnosis and treatment of neoplastic diseases and benign hematologic disorders. Primary emphasis will be placed upon the broad area of medical management. Recent advances in molecular genetics, clinical pharmacology, epidemiology, and supportive care will be stressed. Teaching will be primarily through lectures, panels, and case discussions with the assistance of appropriate visual aids. Participants will be invited to present challenging cases to a faculty panel in a special Wednesday evening session.

Optional Maintenance of Certification (MOC) opportunity for optimum results! Attendees enrolled in ABIM’s Maintenance of Certification (MOC) course and required to earn points towards recertification may attend an optional MOC session on Tuesday evening. This session will guide you through the 2013 Update in Medical Oncology module.

LEARNER OBJECTIVESAfter participating in this program, learners will be able to:

• Evaluate, treat, and manage patients with hematologic disorders more effectively by making appropriate use of current and emerging therapies, cytological characteristics, and molecular diagnostics tests

• Improve care for breast cancer patients by incorporating novel targeted therapies and molecular diagnostics testing into current treatment paradigms

• Create multimodal treatment plans for lung, head, and neck cancers that utilize newly approved therapies and conform more closely to current expert recommendations

• Improve treatment of patients with gastrointestinal and neuroendocrine cancers with more effective uses of molecular diagnostics and available systemic therapies

• Provide care for prostate, testicular, renal, and bladder cancers that is tailored to individual patients and their risk factors and makes appropriate use of new and emerging therapie

Sunday, September 29 - Friday, October 4, 2013

cancer medicine and

hematology

www.cme.hms.harvard.edu/courses/cancermedicine

• Utilize genetic testing, novel treatment approaches, and palliative care to create optimized care plans for patients with ovarian, cervical, endometrial, and trophoblastic cancers

• Incorporate new therapies where available and new clinical trial data into management plans for a wide range of less common cancers, including brain tumors, thyroid cancer, melanoma, sarcoma, and mesothelioma

• Provide effective supportive and palliative care by actively managing pain, depression, dementia, emesis, insomnia, infection, and other aspects of cancer and cancer treatment that can detract from patient quality of life and produce less than optimal outcomes

WHO SHOULD ATTENDMedical Oncologists, Hematologists, Radiation Oncologists, Oncology Surgeons, and Internists

ACGME COMPETENCIESThis course is designed to meet one or more of the following Accreditation Council of Graduate Medical Education competencies:

• Patient Care

• Medical knowledge

• Practice-based learning and improvement and Interpersonal and communication skills

ACCREDITATIONThe Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 51.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria of the Massachusetts Board of Registration in Medicine for 0.75 credits of Risk Management Study. This includes: 0.75 Credits of Opioid Education and Pain Management Training.

Janet L. Abrahm, M.D.Dana-Farber Cancer Institute

Jeremy S. Abramson, M.D.Massachusetts General Hospital

Kenneth C. Anderson, M.D.Dana-Farber Cancer Institute

Tracy T. Batchelor, M.D., M.P.H. Massachusetts General Hospital

Kenneth A. Bauer, M.D.Beth Israel Deaconess Medicine Center

Edward J. Benz, Jr., M.D.Dana-Farber Cancer Institute

Robert A. Brodsky, M.D.Johns Hopkins University

Harold J. Burstein, M.D., Ph.D.Dana-Farber Cancer Institute

John C. Byrd, M.D.Ohio State University

George P. Canellos, M.D.Dana-Farber Cancer Institute

Stephen A. Cannistra, M.D.Beth Israel Deaconess Medical Center

Toni K. Choueiri, M.D.Dana-Farber Cancer Institute

Jean M. Connors, M.D.Brigham and Women’s Hospital

Gilbert Daniels, M.D.Massachusetts General Hospital

Daniel J. DeAngelo, M.D., Ph.D.Dana-Farber Cancer Institute

George D. Demetri, M.D.Dana-Farber Cancer Institute

Walter H. Dzik, M.D.Massachusetts General Hospital

Mark D. Fleming, M.D., D.Phil.Boston Children’s Hospital

Arnold S. Freedman, M.D.Dana-Farber Cancer Institute

Charles S. Fuchs, M.D., M.P.H.Dana-Farber Cancer Institute

Judy E. Garber, M.D., M.P.H.Dana-Farber Cancer Institute

Levi A.Garraway, M.D., Ph.DDana-Farber Cancer Institute

James D. Griffin, M.D.Dana-Farber Cancer Institute

Robert I. Haddad, M.D.Dana-Farber Cancer Institute

Robert I. Handin, M.D.Brigham and Women’s Hospital

Matthew M. Heeney, M.D.Boston Children’s Hospital

F. Stephen Hodi, M.D.Dana-Farber Cancer Institute

Joseph O. Jacobson, M.D.Dana-Farber Cancer Institute

Bruce E. Johnson, M.D.Dana-Farber Cancer Institute

Philip W. Kantoff, M.D.Dana-Farber Cancer Institute

Joel T. Katz, M.D.Brigham and Women’s Hospital

Kenneth Kaushansky, M.D. Stony Brook University

Ian E. Krop, M.D., Ph.D.Dana-Farber Cancer Institute

Matthew H. Kulke, M.D.Dana-Farber Cancer Institute

David J. Kuter, M.D., D.Phil.Massachusetts General Hospital

Thomas J. Lynch, Jr., M.D.Yale Cancer Center

Ursula A. Matulonis, M.D.Dana-Farber Cancer Institute

Robert J. Mayer, M.D.Dana-Farber Cancer Institute

Ellis Neufeld, M.D.Boston Children’s Hospital

Peter E. Newburger, M.D.University of Massachusetts Medical School

William K. Oh, M.D.Mount Sinai School of Medicine

Geoffrey R. Oxnard, M.D. Dana-Farber Cancer Institute

Ann H. Partridge, M.D., M.P.H.Dana-Farber Cancer Institute

Geoffrey I. Shapiro, M.D., Ph.D.Dana-Farber Cancer Institute

Lawrence N. Shulman, M.D.Dana-Farber Cancer Institute

Robert J. Soiffer, M.D.Dana-Farber Cancer Institute

David P. Steensma, M.D.Dana-Farber Cancer Institute

Richard M. Stone, M.D.Dana-Farber Cancer Institute

Sapna Syngal, M.D., M.P.H.Dana-Farber Cancer Institute

Ayalew Tefferi, M.D.Mayo Clinic

Eric P. Winer, M.D.Dana-Farber Cancer Institute

Brian M. Wolpin, M.D.Dana-Farber Cancer Institute


courseschedule


SATURDAY, SEPTEMBER 28, 20136:00 pm - 9:00 pm

Evening Registration

SUNDAY, SEPTEMBER 29, 2013

Presiding: Robert J. Mayer, M.D.

7:00 am Registration

8:45 am Welcome Robert J. Mayer, M.D.

9:00 am Stem Cell Biology and Hematopoietic Growth Factors

David J. Kuter, M.D., D.Phil.

10:00 am Transfusion Medicine for the Clinician Walter H. Dzik, M.D.

11:00 am Break

11:15 am Hemolytic Anemias Jean M. Connors, M.D.

12:15 pm Bone Marrow Failure States Robert A. Brodsky, M.D., Ph.D.

1:15 pm Adjourn

Presiding: David J. Kuter, M.D., D.Phil.

2:15 pm Thrombocytopenias Kenneth Kaushansky, M.D.

3:15 pm Iron Deficiency and Iron Overload Mark D. Fleming, M.D., Ph.D.

4:00 pm Break

4:15 pm Hemoglobinopathies Matthew M. Heeney, M.D.

5:15 pm Leukocyte Disorders Peter E. Newburger, M.D.

6:15 pm Adjourn

MONDAY, SEPTEMBER 30, 2013Presiding: James D. Griffin, M.D.

8:00 am Platelet Function and von Willebrand’s Disease

Robert I. Handin, M.D.

9:00 am Hypercoagulable Syndromes and New Anticoagulant Therapies

Kenneth A. Bauer, M.D.

10:15 am Break

10:30 am Hemophilia-Related Syndromes Ellis J. Neufeld, M.D., Ph.D.

11:30 am Panel Discussion

12:00 pm Adjourn

Presiding: Bruce E. Johnson, M.D.

1:00 pm Molecular Genetics of Cancer Levi A. Garraway, M.D., Ph.D.

2:00 pm Advances in Cancer Drug Development Geoffrey I. Shapiro, M.D., Ph.D.

3:00 pm Break

3:15 pm Infections in the Immunocompromised Host Joel T. Katz, M.D.

4:00 pm Biology of Bone Marrow Transplantation Robert J. Soiffer, M.D.

5:00 pm Adjourn


courseschedule

TUESDAY, OCTOBER 1, 2013

Presiding: Robert J. Soiffer, M.D.

Acute Leukemia and Myelodysplasia:

8:00 am Biology David P. Steensma, M.D.

8:45 am Treatment Richard M. Stone, M.D.

9:45 am Chronic Myelogenous Leukemia Daniel J. De Angelo, M.D., Ph.D.

10:30 am Break

10:45 am Myeloproliferative Syndromes Ayalew Tefferi, M.D.

11:30 am Plasma Cell Neoplasms Kenneth C. Anderson, M.D.

12:30 pm Panel Discussion

1:00 pm Adjourn

Presiding: Richard M. Stone, M.D.

2:00 pm Low Grade Lymphoma Jeremy S. Abramson, M.D.

2:40 pm High Grade Lymphoma Arnold S. Freedman, M.D.

3:30 pm Break

3:45 pm Hodgkin’s Disease George P. Canellos, M.D.

4:30 pm CLL and Variants John C. Byrd, M.D.


5:45 pm Adjourn

7:00 pm - 9:30 pm

ABIM Maintenance of Certification (MOC) Session: 2013 Update in Medical Oncology ModuleHarold J. Burstein, M.D., Ph.D.; Daniel J. DeAngelo, M.D., Ph.D.; Robert J. Mayer, M.D.

WEDNESDAY, OCTOBER 2, 2013

Presiding: Edward J. Benz, Jr., M.D.

8:00 am Neuroendocrine Tumors Matthew H. Kulke, M.D.

Gastrointestinal Malignancies:

8:30 am Genetics and Screening Sapna Syngal, M.D., M.P.H.

9:00 am Esophageal and Gastric Charles S. Fuchs, M.D., M.P.H.

9:45 am Break

10:00 am Pancreas and Hepatobiliary Brian M. Wolpin, M.D.

10:45 am Colorectal and Anal Robert J. Mayer, M.D.


12:15 pm Adjourn

Presiding: Eric P. Winer, M.D.

1:15 pm Sarcoma and GIST George D. Demetri, M.D.

2:15 pm Mesothelioma and Thymic Tumors Geoffrey R. Oxnard, M.D.

3:00 pm Clinical Essentials of Palliative Care Janet L. Abrahm, M.D.

3:45 pm Break

Gynecologic Cancer:

4:00 pm Ovarian Stephen A. Cannistra, M.D.

5:00 pm Cervical, Endometrial, Trophoblastic Ursula A. Matulonis, M.D.


6:15 pm Adjourn8:00 pm - 10:00 pm

Case PresentationHarold J. Burstein, M.D., Ph.D.; George P. Canellos, M.D.; Bruce E. Johnson, M.D.; David J. Kuter, M.D., D.Phil.; Robert J. Mayer, M.D.


courseschedule

THURSDAY, OCTOBER 3, 2013

Presiding: Philip W. Kantoff, M.D.

8:00 am Melanoma F. Stephen Hodi, M.D.

9:00 am Thyroid Cancer Gilbert H. Daniels, M.D.

10:00 am Break

10:15 am Head and Neck Cancer Robert I. Haddad, M.D.

Lung Cancer:

11:15 am Non-Small Cell Thomas J. Lynch, M.D.

12:10 pm Small Cell Bruce E. Johnson, M.D.


1:00 pm Adjourn

Presiding: Lawrence N. Shulman, M.D.

2:00 pm Neuro-Oncology Tracy T. Batchelor, M.D., M.P.H.

Genitourinary Cancer:

3:00 pm Testicular William K. Oh, M.D.

3:45 pm Break

4:00 pm Renal and Bladder Toni K. Choueiri, M.D.

4:45 pm Prostate Philip W. Kantoff, M.D.


6:15 pm Adjourn

7:00 pm - 10:00 pm

Dinner at the Harvard Club“Does Quality Improvement Really Enhance Cancer Care?” - Joseph O. Jacobson, M.D.

FRIDAY, OCTOBER 4, 2013


Breast Cancer:

8:00 am Assessing Breast Cancer Risk and Opportunities for Breast Cancer Prevention

Judy E. Garber, M.D., M.P.H.

8:30 am Advances in Staging, Prognosis, Surgery and Radiation

Harold J. Burstein, M.D, Ph.D.

9:15 am Adjuvant and Neoadjuvant Therapy for Operable Breast Cancer

Eric P. Winer, M.D.

10:00 am Break

10:15 am Management of Metastatic Disease:

HER 2 Negative Disease Lawrence N. Shulman, M.D.

HER 2 Positive Disease Ian E. Krop, M.D., Ph.D.

11:00 am Management and Counseling of Breast Cancer Survivors

Ann H. Partridge, M.D., M.P.H.


12:15 pm Concluding Remarks Robert J. Mayer, M.D.

12:30 pm Course AdjournPlease note: Program changes/ substitutions may be made without notice.


THURSDAY, OCTOBER 3, 2013

Presiding: Philip W. Kantoff, M.D.

8:00 am Melanoma F. Stephen Hodi, M.D.

9:00 am Thyroid Cancer Gilbert H. Daniels, M.D.

10:00 am Break

10:15 am Head and Neck Cancer Robert I. Haddad, M.D.

Lung Cancer:

11:15 am Non-Small Cell Thomas J. Lynch, M.D.

12:10 pm Small Cell Bruce E. Johnson, M.D.


1:00 pm Adjourn

Presiding: Lawrence N. Shulman, M.D.

2:00 pm Neuro-Oncology Tracy T. Batchelor, M.D., M.P.H.

Genitourinary Cancer:

3:00 pm Testicular William K. Oh, M.D.

3:45 pm Break

4:00 pm Renal and Bladder Toni K. Choueiri, M.D.

4:45 pm Prostate Philip W. Kantoff, M.D.


6:15 pm Adjourn

7:00 pm - 10:00 pm

Dinner at the Harvard Club“Does Quality Improvement Really Enhance Cancer Care?” - Joseph O. Jacobson, M.D.

FRIDAY, OCTOBER 4, 2013


Breast Cancer:

8:00 am Assessing Breast Cancer Risk and Opportunities for Breast Cancer Prevention

Judy E. Garber, M.D., M.P.H.

8:30 am Advances in Staging, Prognosis, Surgery and Radiation

Harold J. Burstein, M.D, Ph.D.

9:15 am Adjuvant and Neoadjuvant Therapy for Operable Breast Cancer

Eric P. Winer, M.D.

10:00 am Break

10:15 am Management of Metastatic Disease:

HER 2 Negative Disease Lawrence N. Shulman, M.D.

HER 2 Positive Disease Ian E. Krop, M.D., Ph.D.

11:00 am Management and Counseling of Breast Cancer Survivors

Ann H. Partridge, M.D., M.P.H.


12:15 pm Concluding Remarks Robert J. Mayer, M.D.

12:30 pm Course AdjournPlease note: Program changes/ substitutions may be made without notice.

DISCLOSURE POLICYHarvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers, and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

REFUND POLICYA handling fee of $60 is deducted for cancellation. Refund requests must be received by postal mail, email, or fax one week prior to this activity. No refunds will be made thereafter.

COURSE LOCATIONAll sessions for this course will be held at The Fairmont Copley Plaza Hotel, 138 St. James Avenue, Boston MA 02116 (telephone: 617-267-5300).

ACCOMMODATIONS/TRAVELA limited number of rooms have been reserved at The Fairmont Copley Plaza Hotel (telephone: 617-267-5300) until September 9, 2013. Please specify that you are enrolled in this course to receive a reduced room rate of $299 per night Single/Double. Hotel arrangements can also be made online at:https://resweb.passkey.com/go/danafarber2013. Please do not purchase non-refundable airline ticket(s) until you have received an email from our office confirming your paid registration. For airline reservations, contact the HMS Travel Desk toll free 1-877-4-HARVMD (1-877-442-7863), Monday – Friday, 9:00 AM to8:00 PM (EST). From outside the U.S., Canada, and Virgin Islands, please call 617-559-3764.

cancer medicine and hemotology | September 29 – October 4, 2013 | course #331059

Tuition Fee: $1,500 (USD)

Print Name Clearly – All Fields Required

Full Name First Middle Initial Last

Mailing Address Street City State Zip Code

Daytime Phone ( ) Fax Number ( )

Please note: Your email address is used for critical information about the course, including registration confirmation,

evaluation, and certificate. Please be sure to include an email address you check daily or frequently.

Email Address Please check if you wish to be excluded from receiving email notices of future Harvard Medical School – Department of

Continuing Education programs.

Profession Degree

Primary Specialty (Physicians only) Board Certified: Yes No

Professional School Attended (Physicians only) Harvard Medical School U.S. Medical School

International Year of Graduation

Register early as the course fills up quickly. www.cme.hms.harvard.edu/courses/cancermedicine

cancer medicine and hematology Earn up to 51.75 AMA PRA Crategory 1 Credits™

cancer medicine and hematologySunday, September 29 - Friday, October 4, 2013

✁

Online registrants – add the first three characters of the source code found here

Source code: J W E B K L M X Z Z Z

REGISTRATION INFORMATIONTuition Fee — $1,500 (USD). Registration by credit card (VISA or MasterCard) can be made at: www.cme.hms.harvard.edu/courses/cancermedicine. Registration by check (draft on a United States bank): please make payable to Harvard Medical School and mail with registration form to Harvard Medical School- Department of Continuing Education, PO Box 417476, Boston, MA 02241-7476. Telephone and fax registration is not accepted.

Registration with cash payment is not permitted. Upon receipt of your paid registration, an email confirmation from the HMS-DCE office will be sent to you. Be sure to include an email address that you check frequently. Your email address is used for critical information including: registration confirmation, evaluation, and certificate.

INQUIRIESBy telephone: 617-384-8600, Monday – Friday, 10:00 AM to 4:00 PM (EST) or by email at: [email protected]

ONLINE INFORMATIONTo register or view activity information online, visit www.cme.hms.harvard.edu/courses/cancermedicine.

To ensure proper registration, please add the first three characters of the source code found at the bottom of this registration form.

Health & Medicine

Cancer Medicine and Hematology